Tension headache

Last updated
Tension-type headache (TTH)
Other namesTension headache, stress headache
Tension-headache.jpg
A woman experiencing a tension-type headache
Specialty Neurology
Differential diagnosis Migraine

Tension headache, stress headache, or tension-type headache (TTH), is the most common type of primary headache. The pain usually radiates from the lower back of the head, the neck, the eyes, or other muscle groups in the body typically affecting both sides of the head. Tension-type headaches account for nearly 90% of all headaches.

Contents

Pain medications, such as paracetamol and ibuprofen, are effective for the treatment of tension headache. [1] [2] Tricyclic antidepressants appear to be useful for prevention. [3] Evidence is poor for SSRIs, propranolol and muscle relaxants. [4] [5]

The 2016 Global Burden of Disease study revealed that TTHs affect about 1.89 billion people and are more common in women than men (30.8% to 21.4% respectively). [6] TTH was most prevalent between ages 35 and 39. Despite its benign character, tension-type headache, especially in its chronic form, can impart significant disability on patients as well as burden on society at large. In 2016, the global burden of TTH was reported to be 7.2 million years of life lived with disability (YLDs). The YLD was calculated using TTH prevalence and average time spent with TTH multiplied by percentage health loss caused by TTH (3.7%).

Signs and symptoms

According to the third edition of the International Classification of Headache Disorders, [7] the attacks must meet the following criteria:

Tension-type headaches may be accompanied by tenderness of the scalp on manual pressure during an attack.[ citation needed ]

Risk factors

Various precipitating factors may cause tension-type headaches in susceptible individuals: [8]

Mechanism

Although the musculature of the head and neck and psychological factors such as stress may play a role in the overall pathophysiology of TTH, neither is currently believed to be the sole cause of the development of TTH. [9] The pathologic basis of TTH is most likely derived from a combination of personal factors, environmental factors, and alteration of both peripheral and central pain pathways. [10] Peripheral pain pathways receive pain signals from pericranial (around the head) myofascial tissue (protective tissue of muscles) and alteration of this pathway likely underlies episodic tension-type headache (ETTH). [10] In addition, pericranial muscle tenderness, inflammation, and muscle ischemia have been postulated in headache literature to be causal factors in the peripheral pathophysiology of TTH. [8] However, multiple studies have failed to illustrate evidence for a pathologic role of either ischemia or inflammation within the muscles. [8] Pericranial tenderness is also not likely a peripheral causal factor for TTH, but may instead act to trigger a chronic pain cycle. This is when the peripheral pain response is transformed over time into a centralized pain response. [8] These prolonged alterations in the peripheral pain pathways can lead to increased excitability of the central nervous system pain pathways, resulting in the transition of ETTH into chronic tension-type headache (CTTH). [10] Specifically, the hyperexcitability occurs in central nociceptive neurons (the trigeminal spinal nucleus, thalamus, and cerebral cortex) resulting in central sensitization, which manifests clinically as allodynia and hyperalgesia of CTTH. [8] [11] Additionally, CTTH patients exhibit decreased thermal and pain thresholds which further bolsters support for central sensitization occurring in CTTH. [8]

The alterations in physiology that leads to the overall process of central sensitization, involves changes at the level of neural tracts, neurotransmitters and their receptors, the neural synapse, and the post-synaptic membrane. Evidence also suggests that dysfunction in supraspinal descending inhibitory pain pathways may contribute to the pathogenesis of central sensitization in CTTH. [8]

Neurotransmitters

Specific neuronal receptors and neurotransmitters thought to be most involved include NMDA and AMPA receptors, glutamate, serotonin (5-HT), β-endorphin, and nitric oxide (NO). [8] Of the neurotransmitters, NO plays a major role in central pain pathways and likely contributes to the process of central sensitization. [8] Briefly, the enzyme nitric oxide synthase (NOS) forms NO which ultimately results in vasodilatation and activation of central nervous system pain pathways. [8] Serotonin may also be of significant importance and involved in malfunctioning pain filter located in the brain stem. The view is that the brain misinterprets information—for example from the temporal muscle or other muscles—and interprets this signal as pain. Evidence for this theory comes from the fact that chronic tension-type headaches may be successfully treated with certain antidepressants such as nortriptyline. However, the analgesic effect of nortriptyline, as well as amitriptyline in chronic tension-type headache, is not solely due to serotonin reuptake inhibition, and likely other mechanisms are involved. [12] [8]

Synapses

Regarding synaptic level changes, homosynaptic facilitation and heterosynaptic facilitation are both likely to be involved in central sensitization. [8] Homosynaptic facilitation occurs when synapses normally involved in pain pathways undergo changes involving receptors on the post-synaptic membrane as well as the molecular pathways activated upon synaptic transmission. Lower pain thresholds of CTTH result from this homosynaptic facilitation. In contrast, heterosynaptic facilitation occurs when synapses not normally involved in pain pathways become involved. Once this occurs innocuous signals are interpreted as painful signals. Allodynia and hyperalgesia of CTTH represent this heterosynaptic facilitation clinically. [8]

Stress

In the literature, stress is mentioned as a factor and may be implicated via the adrenal axis. This ultimately results in downstream activation of NMDA receptor activation, NFκB activation, and upregulation of iNOS with subsequent production of NO leading to pain as described above. [8]

Diagnosis

With TTH, the physical exam is expected to be normal with perhaps the exception of either pericranial tenderness upon palpation of the cranial muscles, or presence of either photophobia or phonophobia. [13]

Classification

Classification system for tension-type headache Large headache diagram.png
Classification system for tension-type headache

The International Headache Society's most current classification system for headache disorders is the International Classification of Headache Disorders 3rd edition (ICHD-3) as of 2018. This classification system separates tension-type headache (TTH) into two main groups: episodic (ETTH) and chronic (CTTH). CTTH is defined as fifteen days or more per month with headache for greater than three months, or one-hundred eighty days or more, with headache per year. [14] ETTH is less than fifteen days per month with headache or less than one-hundred eighty days with headache per year. [15] [16] However, ETTH is further sub-divided into frequent and infrequent TTH. [17] Frequent TTH is defined as ten or more episodes of headache over the course of one to fourteen days per month for greater than three months, or at least twelve days per year, but less than one-hundred eighty days per year. [16] Infrequent TTH is defined as ten or more episodes of headache for less than one day per month or less than twelve days per year. [15] Furthermore, all sub-classes of TTH can be classified as having presence or absence of pericranial tenderness, which is tenderness of the muscles of the head. [17] Probable TTH is utilized for patients with some characteristics, but not all characteristics of a given sub-type of TTH. [18]

Differential diagnosis

Extensive testing is not needed as TTH is diagnosed by history and physical examination. However, if symptoms indicative of a more serious diagnosis are present, a contrast enhanced MRI may be utilized. Furthermore, giant cell arteritis should be considered in those 50 years of age and beyond. Screening for giant cell arteritis involves the blood tests of erythrocyte sedimentation rate (ESR) and c-reactive protein. [13] [9]

Prevention

Lifestyle

Good posture might prevent headaches if there is neck pain. [19]

Drinking alcohol can make headaches more likely or severe. [19]

Drinking water and avoiding dehydration helps in preventing tension headache. [19]

People who have jaw clenching might develop headaches, and getting treatment from a dentist might prevent those headaches. [19]

Using stress management and relaxing often makes headaches less likely. [19]

Biofeedback techniques may also help. [20]

Medications

People who have 15 or more headaches in a month may be treated with certain types of daily antidepressants which act to prevent continued tension headaches from occurring. [19] In those who are predisposed to tension type headaches the first-line preventative treatment is amitriptyline, whereas mirtazapine and venlafaxine are second-line treatment options. [21] Tricyclic antidepressants appear to be useful for prevention. [3] Tricyclic antidepressants have been found to be more effective than SSRIs but have greater side effects. [3] Evidence is poor for the use of SSRIs, propranolol, and muscle relaxants for prevention of tension headaches. [4] [5]

Treatment

Treatment for a current tension headache is to drink water and confirm that there is no dehydration. [19] If symptoms do not resolve within an hour for a person who has had water, then stress reduction might resolve the issue. [19]

Exercise

Evidence supports simple neck and shoulder exercises in managing ETTH and CTTH for headaches associated with neck pain. Exercises include stretching, strengthening and range of motion exercises. CTTH can also benefit from combined therapy from stress therapy, exercises and postural correction. [22]

Medications

Episodic

Over-the-counter drugs, like paracetamol, or NSAIDs (ibuprofen, aspirin, naproxen, ketoprofen), can be effective but tend to only be helpful as a treatment for a few times in a week at most. [1] [19] [23] [10] For those with gastrointestinal problems (ulcers and bleeding), and/or kidney problems, acetaminophen is the better choice over aspirin, though both provide roughly equivalent pain relief. [10] It is important to note that large daily doses of paracetamol should be avoided as it may cause liver damage especially in those that consume 3 or more drinks/day and those with pre-existing liver disease. [10] Ibuprofen, one of the NSAIDs listed above, is a common choice for pain relief but may also lead to gastrointestinal discomfort. [10]

Analgesic/caffeine combinations are popular such as the aspirin-caffeine combination or the aspirin, paracetamol and caffeine combinations. [10] Frequent use (daily or skipping just one day in between use for 7–10 days) of any of the above analgesics may, however, lead to medication overuse headache. [2] [21] [10]

Analgesic/sedative combinations are widely used (e.g., analgesic/antihistamine combinations, analgesic/barbiturate combinations such as Fiorinal). [2] [21]

Muscle relaxants are typically used for and are helpful with acute post-traumatic TTH rather than ETTH. [10] Opioid medications are not utilized to treat ETTH. [10] Botulinum toxin does not appear to be helpful. [24]

Chronic

Classes of medications involved in treatment of CTTH include tricyclic antidepressants (TCAs), SSRIs, benzodiazepine (Clonazepam in small evening dose), and muscle relaxants. The most commonly utilized TCA is amitriptyline due to the postulated role in decreasing central sensitization and analgesic relief. Another popular TCA used is Doxepine. SSRIs may also be utilized for management of CTTH. For patients with concurrent muscle spasm and CTTH, the muscle relaxant Tizanidine can be a helpful option. [10]

These medications however, are not effective if concurrent overuse of over the counter medications or other analgesics is occurring. [10] Stopping overuse must occur prior to proceeding with other forms of treatment. [10]

Manual therapy

Current evidence for acupuncture is slight. A 2016 systematic review suggests better evidence among those with frequent tension headaches, but concludes that further trials comparing acupuncture with other treatment options are needed. [25]

People with tension-type headache often use spinal manipulation, soft tissue therapy, and myofascial trigger point treatment. Studies of effectiveness are mixed. A 2006 systematic review found no rigorous evidence supporting manual therapies for tension headache. [26] A 2005 structured review found only weak evidence for the effectiveness of chiropractic manipulation for tension headache, and that it was probably more effective for tension headache than for migraine. [27] Two other systematic reviews published between 2000 and May 2005 did not find conclusive evidence in favor of spinal manipulation. [28] A 2012 systematic review of manual therapy found that hands-on work may reduce both the frequency and the intensity of chronic tension-type headaches. [29] More current literature also appears to be mixed however, CTTH patients may benefit from massage and physiotherapy as suggested by a systemic review examining these modalities via RCTs specifically for this patient population [30] Despite being helpful, the review also makes a point to note that there is no difference in effectiveness long term (6 months) between those CTTH patients utilizing TCAs and physiotherapy. [30] Another systemic review comparing manual therapy to pharmacologic therapy also supports little long term difference in outcome regarding TTH frequency, duration, and intensity. [31]

Epidemiology

As of 2016 tension headaches affect about 1.89 billion people [6] and are more common in women than men (23% to 18% respectively). [32] Despite its benign character, tension-type headache, especially in its chronic form, can impart significant disability on patients as well as burden on society at large. [33]

Related Research Articles

<span class="mw-page-title-main">Antidepressant</span> Class of medication used to treat depression and other conditions

Antidepressants are a class of medications used to treat major depressive disorder, anxiety disorders, chronic pain, and addiction.

<span class="mw-page-title-main">Temporomandibular joint dysfunction</span> Disorders of the muscles and joints connecting the jaw to the skull

Temporomandibular joint dysfunction is an umbrella term covering pain and dysfunction of the muscles of mastication and the temporomandibular joints. The most important feature is pain, followed by restricted mandibular movement, and noises from the temporomandibular joints (TMJ) during jaw movement. Although TMD is not life-threatening, it can be detrimental to quality of life; this is because the symptoms can become chronic and difficult to manage.

<span class="mw-page-title-main">Tricyclic antidepressant</span> Class of medications

Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. TCAs were discovered in the early 1950s and were marketed later in the decade. They are named after their chemical structure, which contains three rings of atoms. Tetracyclic antidepressants (TeCAs), which contain four rings of atoms, are a closely related group of antidepressant compounds.

<span class="mw-page-title-main">Headache</span> Pain in the head, neck, or face

Headache, also known as cephalalgia, is the symptom of pain in the face, head, or neck. It can occur as a migraine, tension-type headache, or cluster headache. There is an increased risk of depression in those with severe headaches.

Chronic pain or chronic pain syndrome is a type of pain that is also known by other titles such as gradual burning pain, electrical pain, throbbing pain, and nauseating pain. This type of pain is sometimes confused with acute pain and can last from three months to several years; various diagnostic manuals such as DSM-5 and ICD-11 have proposed several definitions of chronic pain, but the accepted definition is that it is "pain that lasts longer than the expected period of recovery."

<span class="mw-page-title-main">Fibromyalgia</span> Chronic pain of unknown cause

Fibromyalgia is a medical syndrome that causes chronic widespread pain, accompanied by fatigue, awakening unrefreshed, and cognitive symptoms. Other symptoms can include headaches, lower abdominal pain or cramps, and depression. People with fibromyalgia can also experience insomnia and general hypersensitivity. The cause of fibromyalgia is unknown, but is believed to involve a combination of genetic and environmental factors. Environmental factors may include psychological stress, trauma, and some infections. Since the pain appears to result from processes in the central nervous system, the condition is referred to as a "central sensitization syndrome".

A medication overuse headache (MOH), also known as a rebound headache, usually occurs when painkillers are taken frequently to relieve headaches. These cases are often referred to as painkiller headaches. Rebound headaches frequently occur daily, can be very painful and are a common cause of chronic daily headache. They typically occur in patients with an underlying headache disorder such as migraine or tension-type headache that "transforms" over time from an episodic condition to chronic daily headache due to excessive intake of acute headache relief medications. MOH is a serious, disabling and well-characterized disorder, which represents a worldwide problem and is now considered the third-most prevalent type of headache. The proportion of patients in the population with Chronic Daily Headache (CDH) who overuse acute medications ranges from 18% to 33%. The prevalence of medication overuse headache (MOH) varies depending on the population studied and diagnostic criteria used. However, it is estimated that MOH affects approximately 1-2% of the general population, but its relative frequency is much higher in secondary and tertiary care.

<span class="mw-page-title-main">Pain management</span> Interdisciplinary approach for easing pain

Pain management is an aspect of medicine and health care involving relief of pain in various dimensions, from acute and simple to chronic and challenging. Most physicians and other health professionals provide some pain control in the normal course of their practice, and for the more complex instances of pain, they also call on additional help from a specific medical specialty devoted to pain, which is called pain medicine.

<span class="mw-page-title-main">Duloxetine</span> Antidepressant medication used also for treatment of anxiety and chronic pain

Duloxetine, sold under the brand name Cymbalta among others, is a medication used to treat major depressive disorder, generalized anxiety disorder, obsessive-compulsive disorder, fibromyalgia, neuropathic pain and central sensitization. It is taken by mouth.

<span class="mw-page-title-main">Cyclobenzaprine</span> Muscle relaxant medication

Cyclobenzaprine, sold under several brand names including, historically, Flexeril, is a muscle relaxer used for muscle spasms from musculoskeletal conditions of sudden onset. It is not useful in cerebral palsy. It is taken by mouth.

Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli (allodynia). It may have continuous and/or episodic (paroxysmal) components. The latter resemble stabbings or electric shocks. Common qualities include burning or coldness, "pins and needles" sensations, numbness and itching.

<span class="mw-page-title-main">Orphenadrine</span> Muscle relaxant drug

Orphenadrine is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.

Treatment-resistant depression (TRD) is major depressive disorder in which an affected person does not respond adequately to at least two different antidepressant medications at an adequate dose and for an adequate duration. Inadequate response has most commonly been defined as less than 25% reduction in depressive symptoms following treatment with an antidepressant. Many clinicians and researchers question the construct validity and clinical utility of treatment-resistant depression as currently conceptualized.

<span class="mw-page-title-main">Antimigraine drug</span> Medication intended to reduce the effects or intensity of migraine headache

Antimigraine drugs are medications intended to reduce the effects or intensity of migraine headache. They include drugs for the treatment of acute migraine symptoms as well as drugs for the prevention of migraine attacks.

Mixed tension migraines are also known as mixed migraines or mixed headaches. They combine characteristics of tension headaches and migraines.

New daily persistent headache (NDPH) is a primary headache syndrome which can mimic chronic migraine and chronic tension-type headache. The headache is daily and unremitting from very soon after onset, usually in a person who does not have a history of a primary headache disorder. The pain can be intermittent, but lasts more than 3 months. Headache onset is abrupt and people often remember the date, circumstance and, occasionally, the time of headache onset. One retrospective study stated that over 80% of patients could state the exact date their headache began.

The International Classification of Headache Disorders (ICHD) is a detailed hierarchical classification of all headache-related disorders published by the International Headache Society. It is considered the official classification of headaches by the World Health Organization, and, in 1992, was incorporated into the 10th edition of their International Classification of Diseases (ICD-10). Each class of headache contains explicit diagnostic criteria—meaning that the criteria include quantities rather than vague terms like several or usually—that are based on clinical and laboratory observations.

Preventive treatment of migraine can be an important component of migraine management. The goals of preventive therapy are to reduce the frequency, painfulness, and/or duration of migraine attacks, and to increase the effectiveness of abortive therapy. Another reason to pursue prevention is to avoid medication overuse headache (MOH), otherwise known as rebound headache, which can arise from overuse of pain medications, and can result in chronic daily headache. Preventive treatments of migraine include medications, nutritional supplements, lifestyle alterations, and surgery. Prevention is recommended in those who have headaches more than two days a week, cannot tolerate the medications used to treat acute attacks, or those with severe attacks that are not easily controlled.

<span class="mw-page-title-main">Orofacial pain</span> Pain of the mouth, jaws, or face

Orofacial pain (OFP) is a general term covering any pain which is felt in the mouth, jaws and the face. Orofacial pain is a common symptom, and there are many causes.

An analgesic adjuvant is a medication that is typically used for indications other than pain control but provides control of pain (analgesia) in some painful diseases. This is often part of multimodal analgesia, where one of the intentions is to minimize the need for opioids.

References

  1. 1 2 Derry S, Wiffen PJ, Moore RA, Bendtsen L (July 2015). "Ibuprofen for acute treatment of episodic tension-type headache in adults". The Cochrane Database of Systematic Reviews. 2015 (7): CD011474. doi:10.1002/14651858.CD011474.pub2. PMC   6457940 . PMID   26230487.
  2. 1 2 3 Loder E, Rizzoli P (January 2008). "Tension-type headache". BMJ. 336 (7635): 88–92. doi:10.1136/bmj.39412.705868.AD. PMC   2190284 . PMID   18187725.
  3. 1 2 3 Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, et al. (October 2010). "Tricyclic antidepressants and headaches: systematic review and meta-analysis". BMJ. 341: c5222. doi:10.1136/bmj.c5222. PMC   2958257 . PMID   20961988.
  4. 1 2 Verhagen AP, Damen L, Berger MY, Passchier J, Koes BW (April 2010). "Lack of benefit for prophylactic drugs of tension-type headache in adults: a systematic review". Family Practice. 27 (2): 151–165. doi: 10.1093/fampra/cmp089 . PMID   20028727.
  5. 1 2 Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L (May 2015). "Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults". The Cochrane Database of Systematic Reviews. 2015 (5): CD011681. doi:10.1002/14651858.CD011681. PMC   6864942 . PMID   25931277.
  6. 1 2 Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. (November 2018). "Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016". The Lancet. Neurology. 17 (11): 954–976. doi:10.1016/S1474-4422(18)30322-3. PMC   6191530 . PMID   30353868.
  7. ↑ Headache Classification Committee of the International Headache Society (IHS): The International Classification of Headache Disorders,3rd edition. Cephalalgia 33(9) 629–808
  8. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Chen Y (December 2009). "Advances in the pathophysiology of tension-type headache: from stress to central sensitization". Current Pain and Headache Reports. 13 (6): 484–494. doi:10.1007/s11916-009-0078-x. PMID   19889292. S2CID   36447117.
  9. 1 2 Walls RM, Hockberger RS, Gausche-Hill M (2017-03-09). Rosen's emergency medicine : concepts and clinical practice (Ninth ed.). Philadelphia, PA. p. 1269. ISBN   9780323390163. OCLC   989157341.{{cite book}}: CS1 maint: location missing publisher (link)
  10. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Jay GW, Barkin RL (December 2017). "Primary Headache Disorders- Part 2: Tension-type headache and medication overuse headache". Disease-a-Month. 63 (12): 342–367. doi:10.1016/j.disamonth.2017.05.001. PMID   28886861.
  11. ↑ Ashina S, Bendtsen L, Ashina M (December 2005). "Pathophysiology of tension-type headache". Current Pain and Headache Reports. 9 (6): 415–422. doi:10.1007/s11916-005-0021-8. PMID   16282042. S2CID   21527308.
  12. ↑ Ashina M, Lassen LH, Bendtsen L, Jensen R, Olesen J (January 1999). "Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised crossover trial". Lancet. 353 (9149): 287–289. doi:10.1016/S0140-6736(98)01079-4. PMID   9929022. S2CID   25448414.
  13. 1 2 Smith J (2019). Ferri's Clinical Advisor. Philadelphia: Elsevier. p. 1348. ISBN   978-0-323-53042-2.
  14. ↑ "2.3 Chronic tension-type headache". ICHD-3 The International Classification of Headache Disorders (3rd ed.). Retrieved 2019-01-12.
  15. 1 2 "2.1 Infrequent episodic tension-type headache". ICHD-3 The International Classification of Headache Disorders 3rd edition. Retrieved 2019-01-12.
  16. 1 2 "2.2 Frequent episodic tension-type headache". ICHD-3 The International Classification of Headache Disorders 3rd edition. Retrieved 2019-01-12.
  17. 1 2 "2. Tension-type headache (TTH)". ICHD-3 The International Classification of Headache Disorders 3rd edition. Retrieved 2019-01-12.
  18. ↑ "2.4 Probable tension-type headache". ICHD-3 The International Classification of Headache Disorders 3rd edition. Retrieved 2019-01-12.
  19. 1 2 3 4 5 6 7 8 9 Consumer Reports (28 April 2016). "Tension Headache Treatment and Prevention". Consumer Reports. Retrieved 25 May 2016.
  20. ↑ Nestoriuc Y, Rief W, Martin A (June 2008). "Meta-analysis of biofeedback for tension-type headache: efficacy, specificity, and treatment moderators". Journal of Consulting and Clinical Psychology. 76 (3): 379–396. doi:10.1037/0022-006X.76.3.379. PMID   18540732.
  21. 1 2 3 Bendtsen L, Jensen R (May 2011). "Treating tension-type headache -- an expert opinion". Expert Opinion on Pharmacotherapy. 12 (7): 1099–1109. doi:10.1517/14656566.2011.548806. PMID   21247362. S2CID   207478957.
  22. ↑ Varatharajan S, Ferguson B, Chrobak K, Shergill Y, Côté P, Wong JJ, et al. (July 2016). "Are non-invasive interventions effective for the management of headaches associated with neck pain? An update of the Bone and Joint Decade Task Force on Neck Pain and Its Associated Disorders by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration". European Spine Journal. 25 (7): 1971–1999. doi:10.1007/s00586-016-4376-9. PMID   26851953. S2CID   4393529.
  23. ↑ Derry S, Wiffen PJ, Moore RA (January 2017). "Aspirin for acute treatment of episodic tension-type headache in adults". The Cochrane Database of Systematic Reviews. 1 (1): CD011888. doi:10.1002/14651858.CD011888.pub2. PMC   6464783 . PMID   28084009.
  24. ↑ Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. (May 2016). "Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology". Neurology. 86 (19): 1818–1826. doi:10.1212/WNL.0000000000002560. PMC   4862245 . PMID   27164716.
  25. ↑ Linde K, Allais G, Brinkhaus B, Fei Y, Mehring M, Shin BC, et al. (April 2016). "Acupuncture for the prevention of tension-type headache". The Cochrane Database of Systematic Reviews. 4 (4): CD007587. doi:10.1002/14651858.CD007587.pub2. PMC   4955729 . PMID   27092807.
  26. ↑ Fernández-de-Las-Peñas C, Alonso-Blanco C, Cuadrado ML, Miangolarra JC, Barriga FJ, Pareja JA (2006). "Are manual therapies effective in reducing pain from tension-type headache?: a systematic review". The Clinical Journal of Pain. 22 (3): 278–285. doi:10.1097/01.ajp.0000173017.64741.86. PMID   16514329. S2CID   23367185.
  27. ↑ Biondi DM (June 2005). "Physical treatments for headache: a structured review". Headache. 45 (6): 738–746. doi:10.1111/j.1526-4610.2005.05141.x. PMID   15953306. S2CID   42640492.
  28. ↑ Ernst E, Canter PH (April 2006). "A systematic review of systematic reviews of spinal manipulation". Journal of the Royal Society of Medicine. 99 (4): 192–196. doi:10.1177/014107680609900418. PMC   1420782 . PMID   16574972.
  29. ↑ Chaibi A, Russell MB (July 2012). "Manual therapies for cervicogenic headache: a systematic review". The Journal of Headache and Pain. 13 (5): 351–359. doi:10.1007/s10194-012-0436-7. PMC   3381059 . PMID   22460941.
  30. 1 2 Chaibi A, Russell MB (October 2014). "Manual therapies for primary chronic headaches: a systematic review of randomized controlled trials". The Journal of Headache and Pain. 15 (1): 67. doi: 10.1186/1129-2377-15-67 . PMC   4194455 . PMID   25278005.
  31. ↑ Mesa-Jiménez JA, Lozano-López C, Angulo-Díaz-Parreño S, Rodríguez-Fernández ÁL, De-la-Hoz-Aizpurua JL, Fernández-de-Las-Peñas C (December 2015). "Multimodal manual therapy vs. pharmacological care for management of tension type headache: A meta-analysis of randomized trials". Cephalalgia. 35 (14): 1323–1332. doi:10.1177/0333102415576226. PMID   25748428. S2CID   206521242.
  32. ↑ Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. (December 2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2163–2196. doi:10.1016/S0140-6736(12)61729-2. PMC   6350784 . PMID   23245607.
  33. ↑ Lenaerts ME (December 2006). "Burden of tension-type headache". Current Pain and Headache Reports. 10 (6): 459–462. doi:10.1007/s11916-006-0078-z. PMID   17087872. S2CID   24409468.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.